文献速递消化系统肿瘤

每6个月18FDG-PET/CT监测结直肠癌:一项开放标签多中心随机试验

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.
PubMed 文献 · Ann Oncol · 2018-01-01

该开放标签多中心随机试验纳入239例根治术后缓解期结直肠癌患者,比较常规监测联合每6个月18FDG-PET/CT与常规监测 alone 对治疗失败率的影响。结果显示联合PET/CT组治疗失败率29.2% vs 对照组23.7%(RR=1.23,95%CI 0.80-1.88,P=0.34),无显著改善,但不可切除复发诊断时间显著缩短(7 vs 14.3个月,P=0.016),且平均费用更高。

要点

  • 每6个月18FDG-PET/CT未降低治疗失败率(RR=1.23,P=0.34)。
  • 联合PET/CT组不可切除复发诊断时间显著缩短(7 vs 14.3个月,P=0.016)。
  • 联合PET/CT组平均费用更高(18 192€ vs 11 131€,P<0.033)。

核心结论

  • 在结直肠癌根治术后缓解期患者中,每6个月追加18FDG-PET/CT监测增加费用但未降低治疗失败率。

研究设计与样本

  • 开放标签多中心随机试验,纳入239例根治术后缓解期结直肠癌患者(II期穿孔、III期或IV期),1:1随机分为常规监测组(119例)和常规监测联合每6个月18FDG-PET/CT组(120例),持续3年。

主要发现

  • 治疗失败率:干预组29.2%(31例不可切除复发和4例死亡),对照组23.7%(27例不可切除复发和1例死亡),相对风险=1.23(95%CI 0.80-1.88,P=0.34)。
  • 多因素分析显示无显著差异(风险比=1.33,95%CI 0.8-2.19,P=0.27)。
  • 不可切除复发诊断中位时间:干预组7个月(3-20),对照组14.3个月(7.3-27),P=0.016。
  • 平均每例患者费用:干预组18 192±27 679€,对照组11 131±13€,P<0.033。

临床怎么用

  • 对于结直肠癌根治术后缓解期患者,常规监测已包含密切随访,每6个月追加18FDG-PET/CT未改善治疗失败率且增加费用,不建议常规采用。

局限性

  • 对照组随访非常密切,任何额外的改善(如果存在)可能很小且难以检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18FDG-PET/CT) has high sensitivity for detecting recurrences of colorectal cancer (CRC). Our objective was to determine whether adding routine 6-monthly 18FDG-PET/CT to our usual monitoring strategy improved patient outcomes and to assess the effect on costs. PATIENTS AND METHODS: In this open-label multicentre trial, patients in remission of CRC (stage II perforated, stage III, or stage IV) after curative surgery were randomly assigned (1 : 1) to usual monitoring alone (3-monthly physical and tumour marker assays, 6-monthly liver ultrasound and chest radiograph, and 6-monthly whole-body computed tomography) or with 6-monthly 18FDG-PET/CT, for 3 years. A multidisciplinary committee reviewed each patient's data every 3 months and classified the recurrence status as yes/no/doubtful. Recurrences were treated with curative surgery alone if feasible and with chemotherapy otherwise. The primary end point was treatment failure defined as unresectable recurrence or death. Relative risks were estimated, and survival was analysed using the Kaplan-Meier method, log-rank test, and Cox models. Direct costs were compared. RESULTS: Of the 239 enrolled patients, 120 were in the intervention arm and 119 in the control arm. The failure rate was 29.2% (31 unresectable recurrences and 4 deaths) in the intervention group and 23.7% (27 unresectable recurrences and 1 death) in the control group (relative risk = 1.23; 95% confidence interval, 0.80-1.88; P = 0.34). The multivariate analysis also showed no significant difference (hazards ratio, 1.33; 95% confidence interval, 0.8-2.19; P = 0.27). Median time to diagnosis of unresectable recurrence (months) was significantly shorter in the intervention group [7 (3-20) versus 14.3 (7.3-27), P = 0.016]. Mean cost/patient was higher in the intervention group (18 192 ± 27 679 € versus 11 131 ± 13 €, P < 0.033). CONCLUSION: 18FDG-PET/CT, when added every 6 months, increased costs without decreasing treatment failure rates in patients in remission of CRC. The control group had very close follow-up, and any additional improvement (if present) would be small and hard to detect. CLINICALTRIALS.GOV IDENTIFIER: NCT00624260.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sobhani I, Itti E, Luciani A, et al. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. Ann Oncol. 2018. PMID: 29365058. doi:10.1093/annonc/mdy031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。